Arcutis Biotherapeutics (ARQT) Stock Forecast & Price Target

Arcutis Biotherapeutics is positioned as a differentiated commercial-stage dermatology franchise built around ZORYVE, a potent PDE4 inhibitor approved across plaque psoriasis, atopic dermatitis, and seborrheic dermatitis, with the foam and cream formulations tailored to distinct high-unmet-need use cases. The fundamental bull case is reinforced by rapid commercial execution: ZORYVE sales rose from $29M in 2023 to $167M in 2024 and $372M in 2025, while 2Q26 sales of $129.9M increased 59% year over year and helped lift 2026 net product sales guidance to $525M-$540M. Additional upside comes from leadership in seborrheic dermatitis with limited direct branded competition, expanding pediatric and scalp psoriasis access, improving cash generation, and optionality from vitiligo, hidradenitis suppurativa, and ARQ-234 data.

Arcutis Biotherapeutics is viewed negatively because its Zoryve growth thesis depends on multiple approvals and timely regulatory execution that are not guaranteed, including the 2/23/27 PDUFA for Zoryve cream 0.05% in infants with atopic dermatitis, while scalp psoriasis still requires approval. The company also faces meaningful commercialization risk from generic topical competitors and Vtama, plus payer access hurdles that could force heavier gross-to-net discounts and pressure the 2026E guide of $525–$540M. In addition, escalating operating expenses, reliance on Interquim for manufacturing, and the need for additional capital increase dilution and execution risk if uptake in approved indications is slower than expected.